Dong, Daifeng
Ironside, Maria
Belleau, Emily L.
Sun, Xiaoqiang
Cheng, Chang
Xiong, Ge
Nickerson, Lisa D.
Wang, Xiang
Yao, Shuqiao http://orcid.org/0000-0001-6681-6844
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Funding for this research was provided by:
China Scholarship Council
Article History
Received: 4 June 2021
Revised: 19 November 2021
Accepted: 30 November 2021
First Online: 10 January 2022
Competing interests
: Over the past 3 years, DAP has received consulting fees from BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Neurocrine Biosciences, Neuroscience Software, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes, and research funding from NIMH, Dana Foundation, Brain and Behavior Research Foundation, Millennium Pharmaceuticals. In addition, he has received stock options from BlackThorn Therapeutics. All views expressed are solely those of the authors. All other authors report no financial relationships with commercial interest.